Cancer signaling networks play key roles in cancer pathogenesis and drug discovery. The RAS/RAF/MAPK pathway has a crucial role in cell biology and cancer progression, with Raf-1 proto-oncogene, serine/threonine kinase (RAF1) serving as a key regulatory protein in this pathway. This study presents a comprehensive analysis of site-specific phosphorylation of RAF1 and its potential implications in cancer development and therapeutics. Through comprehensive analysis of human cellular phosphoproteomic datasets (769 qualitatively profiled and 196 quantitatively differentially expressed), we identified 63 phosphorylation sites on RAF1. Among these, 29 sites demonstrated distinct regulatory effects in various contexts, including cancer, infections, and signaling-related studies. Notably, our analysis revealed that the most prevalent phosphorylation sites, S259, S621, S642, S296, S301, and S43 primarily regulate kinase-independent RAF1 signaling. This observation suggests a complex interplay between phosphorylation events and RAF1 function, beyond its canonical kinase activity. By elucidating these regulatory mechanisms, our study provides valuable insights into the intricate regulation of RAF1 and its potential impact on cancer-related signaling pathways. These findings not only advance the current understanding of RAF1 regulation but also open new possibilities for the development of targeted therapeutic interventions for cancer treatment. Further investigation of these phosphorylation sites and their functional consequences may lead to novel strategies for cancer treatment innovation by modulating RAF1 activity in cancer cells.
Get full access to this article
View all access options for this article.
References
1.
AasebøE, BervenFS, HovlandR, et al.The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. Cancers, 2020; 12(6):1466; doi: 10.3390/cancers12061466
2.
AbeY, TadaA, IsoyamaJ, et al.Improved phosphoproteomic analysis for phosphosignaling and active-kinome profiling in Matrigel-embedded spheroids and patient-derived organoids. Sci Rep, 2018; 8(1):11401; doi: 10.1038/s41598-018-29837-1
3.
Abu-ThuraiaA, GoyetteM-A, BoulaisJ, et al.AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network. Nat Commun, 2020; 11(1):3586; doi: 10.1038/s41467-020-17415-x
4.
AraiH, BattaglinF, WangJ, et al.Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev, 2019; 81:101912; doi: 10.1016/j.ctrv.2019.101912
BaharME, KimHJ, KimDR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. Signal Transduct Target Ther, 2023; 8(1):455; doi: 10.1038/s41392-023-01705-z
7.
BalanV, LeichtDT, ZhuJ, et al.Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell, 2006; 17(3):1141–1153; doi: 10.1091/mbc.e04-12-1123
8.
BekeleRT, SamantAS, NassarAH, et al.RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. J Clin Invest, 2021; 131(22):e147849; doi: 10.1172/JCI147849
9.
BeliP, LukashchukN, WagnerSA, et al.Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell, 2012; 46(2):212–225; doi: 10.1016/j.molcel.2012.01.026
10.
Ben MousaA. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol, 2008; 14(1):40–42; doi: 10.4103/1319-3767.37808
11.
BludauI, WillemsS, ZengWF, et al.The structural context of posttranslational modifications at a proteome-wide scale. PLoS Biol, 2022; 20(5):e3001636; doi: 10.1371/journal.pbio.3001636
12.
BlumenscheinGJr, Sorafenib in lung cancer: Clinical developments and future directions. J Thorac Oncol, 2008; 3(Suppl 2):S124–S127; doi: 10.1097/JTO.0b013e318174e085
13.
BoichukS, Rausch J, DuensingA. New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy, 2014; 4:1–10.
14.
BonnerT, O’BrienSJ, NashWG, et al.The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. Science, 1984; 223(4631):71–74; doi: 10.1126/science.6691137
15.
Broecker-PreussM, MüllerS, BrittenM, et al.Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer, 2015; 15:184; doi: 10.1186/s12885-015-1186-0
ChinPC, LiuLI, MorrisonBE, et al.The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem, 2004; 90(3):595–608; doi: 10.1111/j.1471-4159.2004.02530.x
18.
ChongH, VikisHG, GuanKL. Mechanisms of regulating the Raf kinase family. Cell Signal, 2003; 15(5):463–469; doi: 10.1016/s0898-6568(02)00139-0
19.
CunninghamDL, SarhanAR, CreeseAJ, et al.Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study. Sci Rep, 2020; 10(1):7950; doi: 10.1038/s41598-020-64534-y
20.
CutlerREJr, StephensRM, SaracinoMR, et al.Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A, 1998; 95(16):9214–9219; doi: 10.1073/pnas.95.16.9214
21.
DattachoudhuryS, SharmaR, KumarA, et al.Sorafenib inhibits proliferation, migration and invasion of breast cancer cells. Oncology, 2020; 98(7):478–486; doi: 10.1159/000505521
22.
de GraafEL, GiansantiP, AltelaarAF, et al.Single-step enrichment by Ti4+-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. Mol Cell Proteomics, 2014; 13(9):2426–2434; doi: 10.1074/mcp.O113.036608
23.
DeNardoBD, HollowayMP, JiQ, et al.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One, 2013; 8(12):e82513; doi: 10.1371/journal.pone.0082513
24.
DhillonAS, PollockC, SteenH, et al.Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol, 2002; 22(10):3237–3246; doi: 10.1128/MCB.22.10.3237-3246.2002
25.
DhillonAS, YipYY, GrindlayGJ, et al.The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal, 2009; 21(11):1645–1651; doi: 10.1016/j.cellsig.2009.07.001
26.
DinkelH, ChicaC, ViaA, et al.Phospho.ELM: A database of phosphorylation sites–update 2011. Nucleic Acids Res, 2011; 39(Database issue):D261–D267; doi: 10.1093/nar/gkq1104
27.
DollS, UrismanA, Oses-PrietoJA, ArnottD, BurlingameAL. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma. Mol Cell Proteomics, 2017; 16(1):39–56; doi: 10.1074/mcp.M116.063883
28.
DorardC, MadryC, BuhardO, et al.RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status. Oncogene, 2023; 42(20):1649–1660; doi: 10.1038/s41388-023-02683-w
29.
DoughertyMK, MullerJ, RittDA, et al.Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell, 2005; 17(2):215–224; doi: 10.1016/j.molcel.2004.11.055
30.
DurrantDE, MorrisonDK. Targeting the Raf kinases in human cancer: The Raf dimer dilemma. Br J Cancer, 2018; 118(1):3–8; doi: 10.1038/bjc.2017.399
31.
FengR, GongJ, WuL, et al.MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma. Oncol Rep, 2017; 38(2):1199–1205; doi: 10.3892/or.2017.5774
32.
FengY, SpeziaM, HuangS, et al.Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis, 2018; 5(2):77–106; doi: 10.1016/j.gendis.2018.05.001
33.
FunkeL, BrachtT, OeckS, et al.NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C. Cancers, 2021; 13(21):5293; doi: 10.3390/cancers13215293
34.
GalanJA, GeraghtyKM, LavoieG, et al.Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. Proc Natl Acad Sci U S A, 2014; 111(29):E2918–E2927; doi: 10.1073/pnas.1405601111
35.
GoelR, HarshaHC, PandeyA, et al.Human protein reference database and human Proteinpedia as resources for phosphoproteome analysis. Mol Biosyst, 2012; 8(2):453–463; doi: 10.1039/c1mb05340j
36.
GräfJF, MikicicI, PingX, et al.Substrate spectrum of PPM1D in the cellular response to DNA double-strand breaks. iScience, 2022; 25(9):104892; doi: 10.1016/j.isci.2022.104892
37.
GredingerE, GerberAN, TamirY, et al.Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem, 1998; 273(17):10436–10444; doi: 10.1074/jbc.273.17.10436
38.
GuoYJ, PanWW, LiuSB, et al.ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med, 2020; 19(3):1997–2007; doi: 10.3892/etm.2020.8454
39.
HamaokaY, NegishiM, KatohH. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation. Biochem Biophys Res Commun, 2018; 499(4):920–926; doi: 10.1016/j.bbrc.2018.04.020
40.
HindleyA, KolchW. Raf-1 and B-Raf promote protein kinase C theta interaction with BAD. Cell Signal, 2007; 19(3):547–555; doi: 10.1016/j.cellsig.2006.08.004
41.
HolderfieldM, MerrittH, ChanJ, et al.RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell, 2013; 23(5):594–602; doi: 10.1016/j.ccr.2013.03.033
42.
HornbeckPV, ZhangB, MurrayB, et al.PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res, 2015; 43(Database issue):D512–D520; doi: 10.1093/nar/gku1267
43.
HuangC, FosterSR, ShahAD, et al.Phosphoproteomic characterization of the signaling network resulting from activation of the chemokine receptor CCR2. J Biol Chem, 2020; 295(19):6518–6531; doi: 10.1074/jbc.RA119.012026
44.
HuangKY, WuHY, ChenYJ, et al.RegPhos 2.0: An updated resource to explore protein kinase-substrate phosphorylation networks in mammals. Database (Oxford), 2014; 2014:bau034; doi: 10.1093/database/bau034
45.
ImielinskiM, GreulichH, KaplanB, et al.Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest, 2014; 124(4):1582–1586; doi: 10.1172/JCI72763
46.
JilaveanuLB, ZitoCR, AzizSA, et al.C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res, 2009; 15(18):5704–5713; doi: 10.1158/1078-0432.CCR-09-0198
47.
JohnL, GeorgeM, DcunhaL, et al.Elucidating the phosphoregulatory network of predominant phosphosite in AXL kinase: An integrative bioinformatic approach. J Proteins Proteom, 2024; 15(3):429–447; doi: 10.1007/s42485-024-00147-7
48.
JohnsonJL, YaronTM, HuntsmanEM, et al.An atlas of substrate specificities for the human serine/threonine kinome. Nature, 2023; 613(7945):759–766; doi: 10.1038/s41586-022-05575-3
49.
KamburovA, HerwigR. ConsensusPathDB 2022: Molecular interactions update as a resource for network biology. Nucleic Acids Res, 2022; 50(D1):D587–D595; doi: 10.1093/nar/gkab1128
50.
KangDC, SuZZ, SarkarD, et al.Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene, 2005; 353(1):8–15; doi: 10.1016/j.gene.2005.04.006
51.
KaukoO, LaajalaTD, JumppanenM, et al.Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep, 2015; 5:13099; doi: 10.1038/srep13099
52.
KolbergL, RaudvereU, KuzminI, et al.g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res, 2023; 51(W1):W207–W212; doi: 10.1093/nar/gkad347
53.
KolchW, HeideckerG, KochsG, et al.Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature, 1993; 364(6434):249–252; doi: 10.1038/364249a0
54.
LeichtDT, BalanV, KaplunA, et al.Raf kinases: Function, regulation and role in human cancer. Biochim Biophys Acta, 2007; 1773(8):1196–1212; doi: 10.1016/j.bbamcr.2007.05.001
55.
LeontovichAA, ZhangS, QuatraroC, et al.Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol, 2012; 40(6):1858–1864; doi: 10.3892/ijo.2012.1407
56.
LiW, MelnickM, PerrimonN. Dual function of Ras in Raf activation. Development, 1998; 125(24):4999–5008; doi: 10.1242/dev.125.24.4999
57.
LiZ, LaiZW, ChristianoR, et al.Global analyses of selective insulin resistance in hepatocytes caused by palmitate Lipotoxicity. Mol Cell Proteomics, 2018; 17(5):836–849; doi: 10.1074/mcp.RA117.000560
58.
LimJY, KimH, JeunSS, et al.Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun, 2006; 340(4):1151–1157; doi: 10.1016/j.bbrc.2005.12.122
59.
LimSH, JungJ, HongJY, et al.Prevalence of RAF1 aberrations in metastatic cancer patients: Real-World data. Biomedicines, 2023; 11(12):3264; doi: 10.3390/biomedicines11123264
60.
LindingR, JensenLJ, PasculescuA, et al.NetworKIN: A resource for exploring cellular phosphorylation networks. Nucleic Acids Res, 2008; 36(Database issue):D695–D699; doi: 10.1093/nar/gkm902
61.
LiuL, CaoY, ChenC, et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006; 66(24):11851–11858; doi: 10.1158/0008-5472.CAN-06-1377
62.
LongQI, FengL, LiY, et al.Time-resolved quantitative phosphoproteomics reveals cellular responses induced by caffeine and coumarin. Toxicol Appl Pharmacol, 2022; 449:116115; doi: 10.1016/j.taap.2022.116115
MasonCS, SpringerCJ, CooperRG, et al.Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J, 1999; 18(8):2137–2148; doi: 10.1093/emboj/18.8.2137
65.
MatallanasD, BirtwistleM, RomanoD, et al.Raf family kinases: Old dogs have learned new tricks. Genes Cancer, 2011; 2(3):232–260; doi: 10.1177/1947601911407323
66.
MebratuY, TesfaigziY. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle, 2009; 8(8):1168–1175; doi: 10.4161/cc.8.8.8147
67.
MigliaccioN, SangesC, RuggieroI, et al.Raf kinases in signal transduction and interaction with translation machinery. Biomol Concepts, 2013; 4(4):391–399; doi: 10.1515/bmc-2013-0003
68.
MischakH, SeitzT, JanoschP, et al.Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol, 1996; 16(10):5409–5418; doi: 10.1128/MCB.16.10.5409
69.
NarushimaY, Kozuka-HataH, Koyama-NasuRYO, et al.Integrative Network Analysis Combined with Quantitative Phosphoproteomics Reveals Transforming Growth Factor-beta Receptor type-2 (TGFBR2) as a Novel Regulator of Glioblastoma Stem Cell Properties. Mol Cell Proteomics, 2016; 15(3):1017–1031; doi: 10.1074/mcp.M115.049999
70.
NisarM, SomanSP, SreelanS, et al.ProteoArk: A one-pot proteomics data analysis and visualization tool for biologists. J Proteome Res, 2025; 24(3):1008–1016; doi: 10.1021/acs.jproteome.4c00556
71.
NobleC, MercerK, HussainJ, et al.CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell, 2008; 31(6):862–872; doi: 10.1016/j.molcel.2008.08.026
72.
NolanAA, AboudNK, KolchW, et al.Hidden targets in RAF Signalling pathways to block oncogenic RAS signalling. Genes (Basel), 2021; 12(4):553; doi: 10.3390/genes12040553
73.
OkanishiH, OhgakiR, OkudaS, EndouH, KanaiY. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Sci, 2021; 112(2):871–883; doi: 10.1111/cas.14756
74.
OkanishiH, OhgakiR, XuM, et al.Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1. Cancer Metab, 2022; 10(1):18; doi: 10.1186/s40170-022-00295-8
75.
OkudaK, MatulonisU, SalgiaR, et al.Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol, 1994; 22(11):1111–1117.
76.
OppermannFS, KlammerM, BobeC, et al.Comparison of SILAC and mTRAQ quantification for phosphoproteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res, 2013; 12(9):4089–4100; doi: 10.1021/pr400417g
77.
OughtredR, RustJ, ChangC, et al.The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci, 2021; 30(1):187–200; doi: 10.1002/pro.3978
78.
ParcaL, ArianoB, CabibboA, et al.Kinome-wide identification of phosphorylation networks in eukaryotic proteomes. Bioinformatics, 2019; 35(3):372–379; doi: 10.1093/bioinformatics/bty545
79.
PolzienL, BaljulsA, RennefahrtUEE, et al.Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: Pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem, 2009; 284(41):28004–28020; doi: 10.1074/jbc.M109.010702
80.
PossZC, EbmeierCC, OdellAT, et al.Identification of mediator kinase substrates in human cells using Cortistatin A and quantitative Phosphoproteomics. Cell Rep, 2016; 15(2):436–450; doi: 10.1016/j.celrep.2016.03.030
81.
RaghuDH, DcunhaL, AhmedM, et al.Unravelling the phosphoregulatory network of protein kinase C-delta (PKC-δ). Biochim Biophys Acta Proteins Proteom, 2025; 1873(5):141080; doi: 10.1016/j.bbapap.2025.141080
82.
ReigstadA, HerdleværCF, RiggE, et al.CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. PLoS One, 2022; 17(9):e0273711; doi: 10.1371/journal.pone.0273711
83.
RizzoMA, ShomeK, WatkinsSC, et al.The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem, 2000; 275(31):23911–23918; doi: 10.1074/jbc.M001553200
84.
RoolfC, DybowskiN, SekoraA, et al.Phosphoproteome analysis reveals differential mode of action of Sorafenib in wildtype and mutated FLT3 Acute Myeloid Leukemia (AML) cells. Mol Cell Proteomics, 2017; 16(7):1365–1376; doi: 10.1074/mcp.M117.067462
85.
RuprechtB, ZaalEA, ZechaJ, et al.Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis. Cancer Res, 2017; 77(8):1842–1853; doi: 10.1158/0008-5472.Can-16-2976
86.
SanjeevD, GeorgeM, JohnL, et al.Tyr352 as a predominant Phosphosite in the understudied kinase and molecular target, HIPK1: Implications for cancer therapy. OMICS, 2024a;28(3):111–124; doi: 10.1089/omi.2023.0244
87.
SanjeevD, MendonS, GeorgeM, et al.Exploring the phospho-landscape of NEK6 kinase: Systematic annotation of phosphosites and their implications as biomarkers in carcinogenesis. J Proteins Proteom, 2024b;15(3):377–393; doi: 10.1007/s42485-024-00146-8
88.
SchreiberTB, MäusbacherN, KériG, CoxJ, DaubH. An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics, 2010; 9(6):1047–1062; doi: 10.1074/mcp.M900486-MCP200
89.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
90.
ShaoX, GramsC, GaoY. Sequence coverage visualizer: A web application for protein sequence coverage 3D visualization. J Proteome Res, 2023; 22(2):343–349; doi: 10.1021/acs.jproteome.2c00358
91.
SheelaA, MahinA, UmmarS, et al.Phosphoproteomic analysis of CARMIL1 Reveals novel regulatory mechanisms and upstream kinases involved in actin dynamics and cell migration. Cytoskeleton (Hoboken), 2025, doi: 10.1002/cm.70001
92.
SurveSV, MyersPJ, ClaytonSA, et al.Localization dynamics of endogenous fluorescently labeled RAF1 in EGF-stimulated cells. Mol Biol Cell, 2019; 30(4):506–523; doi: 10.1091/mbc.E18-08-0512
93.
ThielG, EkiciM, RosslerOG. Regulation of cellular proliferation, differentiation and cell death by activated Raf. Cell Commun Signal, 2009; 7:8; doi: 10.1186/1478-811X-7-8
94.
TianH, YangZ, HeJ. Adagrasib: A landmark in the KRAS(G12C)-mutated NSCLC. MedComm (2020), 2022; 3(4):e190; doi: 10.1002/mco2.190
95.
TranNH, FrostJA. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem, 2003; 278(13):11221–11226; doi: 10.1074/jbc.M210318200
96.
TsitsiridisG, SteinkampR, GiurgiuM, et al.CORUM: The comprehensive resource of mammalian protein complexes-2022. Nucleic Acids Res, 2023; 51(D1):D539–D545; doi: 10.1093/nar/gkac1015
97.
UniProtC. UniProt: The universal protein knowledgebase in 2023. Nucleic Acids Res, 2023; 51(D1):D523–D531; doi: 10.1093/nar/gkac1052
98.
VyseS, McCarthyF, BroncelM, et al.Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J Proteomics, 2018; 170:130–140; doi: 10.1016/j.jprot.2017.08.015
99.
WalkerF, KatoA, GonezLJ, et al.Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol Cell Biol, 1998; 18(12):7192–7204; doi: 10.1128/MCB.18.12.7192
100.
WangD, ZhangW, ZhangX, et al.Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase. Mol Carcinog, 2023a;62(4):517–531; doi: 10.1002/mc.23503
101.
WatsonJ, FergusonHR, BradyRM, et al.Spatially resolved phosphoproteomics reveals fibroblast growth factor receptor recycling-driven regulation of autophagy and survival. Nat Commun, 2022; 13(1):6589; doi: 10.1038/s41467-022-34298-2
102.
WangM, KluinPM, RosatiS, et al.Raf-1 Is Over Expressed in Chronic Lymphocytic Leukemia and Promotes Cell Survival by Phosphorylation of ERK and BAD. Blood, 2008; 112(11):3120–3120; doi: 10.1182/blood.V112.11.3120.3120
103.
WangP, LasterK, JiaX, et al.Targeting CRAF kinase in anti-cancer therapy: Progress and opportunities. Mol Cancer, 2023b;22(1):208; doi: 10.1186/s12943-023-01903-x
104.
WilsonMA, ZhaoF, KhareS, et al.Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and Sorafenib in melanoma. Clin Cancer Res, 2016; 22(2):374–382; doi: 10.1158/1078-0432.Ccr-15-1162
105.
WirbelJ, CutillasP, Saez-RodriguezJ. Phosphoproteomics-Based profiling of kinase activities in cancer cells. Methods Mol Biol, 2018; 1711:103–132; doi: 10.1007/978-1-4939-7493-1_6
106.
WuX, MaoF, LiN, et al.NF2/Merlin suppresses proliferation and induces apoptosis in colorectal cancer cells. Front Biosci (Landmark Ed), 2020; 25(3):513–525; doi: 10.2741/4817
107.
YangS, LiuG. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett, 2017; 13(3):1041–1047; doi: 10.3892/ol.2017.5557
108.
ZangM, GongJ, LuoL, et al.Characterization of Ser338 phosphorylation for Raf-1 activation. J Biol Chem, 2008; 283(46):31429–31437; doi: 10.1074/jbc.M802855200
109.
ZhangZ, ZhangY, LiY, et al.Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol, 2022; 449:116110; doi: 10.1016/j.taap.2022.116110
110.
ZhaoJ, LuoZ. Discovery of Raf family is a milestone in deciphering the Ras-Mediated intracellular signaling pathway. Int J Mol Sci, 2022; 23(9):5158; doi: 10.3390/ijms23095158
111.
ZimmermannS, MoellingK. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science, 1999; 286(5445):1741–1744; doi: 10.1126/science.286.5445.1741
